Key result
Angiotensin II and endothelial dysfunction drive hypertensive heart disease, supporting ACE inhibitor use.
Why the study?
The cellular and molecular mechanisms by which hypertension causes vascular and cardiac disease are beginning to be understood but require further clarification.
Design
Review
Authors
Loading...
ACEIs may remain preferred in hypertensive CVD; leaves open need for updated RCTs vs contemporary agents.
This review highlights the central role of Angiotensin II in hypertensive cardiovascular disease and supports the use of converting enzyme inhibitors as preferred antihypertensive therapy.
Juan A. Oliver (1993) conducted a review in Hypertension and cardiovascular disease. Angiotensin II and endothelium-derived relaxing factor abnormalities are central to hypertensive cardiovascular disease pathogenesis, supporting the use of converting enzyme inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: